A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase

Cancer Research

Volumn 57, Issue 6, 1997, Pages 1020-1022

  Makridakis, Nick ^a   Ross, Ronald K ^a   Pike, Malcolm C ^a   Chang, Lilly ^a   Stanczyk, Frank Z ^a   Kolonel, Laurence N ^b   Shi, Chen Yang ^c   Yu, Mimi C ^a   Henderson, Brian E ^a   Reichardt, Juergen K V ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID 5ALPHA REDUCTASE;

AMINO ACID SUBSTITUTION; ARTICLE; ASIAN; CAUCASIAN; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MISSENSE MUTATION; NEGRO; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE;

ALLELES; CODON; COHORT STUDIES; CONTINENTAL POPULATION GROUPS; DIHYDROTESTOSTERONE; DISEASE SUSCEPTIBILITY; GENE FREQUENCY; HUMANS; MALE; POINT MUTATION; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0030938257     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. CA Cancer J. Clin., 65: 5-27, 1996.
2. Bernstein, L., and Ross, R. K. Cancer in Los Angeles County. A Portrait of Incidence and Mortality. University of Southern California, pp. 56-57, 1991.
3. Ross, R. K., Bernstein, L., Lobo, R. A., Shimizu, H., Stanczyk, F. Z., Pike, M. C., and Henderson, B. E. 5-α-Reductase activity and risk of prostate cancer among Japanese and U.S. white and black males. Lancet, 339: 887-889, 1992.
4. Gann, P. H., Hennekens, C. H., Ma, J., Loncope, C., and Stampfer, M. J. Prospective study of sex hormone levels and risk of prostate cancer. J. Natl. Cancer Inst., 88: 1118-1125, 1996.
5. The prognosis for prostate cancer. Nat. Gen., 6: 215-216, 1994.
6. Cannon-Albright, L., and Eeles, R. Progress in prostate cancer. Nat. Gen., 9: 336-338, 1995.
7. Coffey, D. S. The molecular biology of the prostate. In: H. Lepor and R. K. Lawson (eds.). Prostate Diseases, pp. 28-56. Philadelphia: W. B. Saunders, 1993.
8. Wilson, J. D., Griffin, J. E., and Russell, D. W. Steroid 5α-reductase deficiency. Endocr. Rev., 14: 577-593, 1993.
9. Labrie, F., Sugimoto, Y., Luu-The, V., Simard, J., Lachance, Y., Bachvarov, D., Leblanc, G., Durocher, F., and Paquet, N. Structure of the human type II 5α-reductase gene. Endocrinology, 131: 1571-1573, 1992.
10. Thigpen, A. E., Davis, D. L., Milatovitch, A., Mendonca, B. B., Imperato-Ginley, J., Griffin, J. E., Francke, U., Wilson, J. D., and Russell. D. W. Molecular genetics of steroid 5α-reductase 2 deficiency. J. Clin. Invest., 90: 799-809, 1992.
11. Reichardt, J. K. V., Makridakis, N., Henderson, B. E., Yu, M. C., Pike, M. C., and Ross, R. K. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res., 55: 3973-3975, 1995.
12. Davis, D. L., and Russell, D. W. Unusual length polymorphism in human steroid 5α-reductase type 2 gene (SRD5A2). Hum. Mol. Genet., 2: 820, 1993.
13. Wong, I. L., Morris, R. S., Chang, L., Spahn, M-A., Stanczyk, F. Z., and Lobo, R. A prospective randomized trial comparing Finasteride to spironolactone in the treatment of hirsute women. J. Clin. Endocrinol. Metabol., 80: 233-239, 1995.
14. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning. Ed. 2. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
15. Wigley, W. C., Prihoda, J. S., Mowszowicz, I., Mendonca, B. B., New, M. I., Wilson, J. D., and Russell, D. W. Natural mutagenesis of the human steroid 5α-reductase 2 isozyme. Biochemistry, 33: 1265-1270, 1994.
16. Colton, T. Statistics in Medicine. Boston: Little Brown, 1974.
17. Horton, R., and Lobo, R. Peripheral androgen metabolism and the role of androstanediol glucuronide. In: R. Horton and R. Lobo (eds.), Clinics in Endocrinology and Metabolism, Vol. 15, pp. 293-306. Philadelphia: W. B. Saunders, 1986.